Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03)

Journal of Bone and Mineral Metabolism

Volumn 32, Issue 3, 2014, Pages 298-304

  Tanaka, Shiro ^a   Miyazaki, Teruhiko ^b   Uemura, Yukari ^c   Kuroda, Tatsuhiko ^b   Miyakawa, Nobuaki ^b   Nakamura, Toshitaka ^d   Fukunaga, Masao ^e   Ohashi, Yasuo ^c   Ohta, Hiroaki ^f   Mori, Satoshi ^g   Hagino, Hiroshi ^h   Hosoi, Takayuki ⁱ   Sugimoto, Toshitsugu ^j   Itoi, Eiji ^k   Orimo, Hajime ^l   Shiraki, Masataka ^m  

^a KYOTO UNIVERSITY   (Japan)

^b Nishiyama Kogyo Ochanomizu Building 5F   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^e KAWASAKI MEDICAL SCHOOL   (Japan)

^f INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^g SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

^h TOTTORI UNIVERSITY   (Japan)

ⁱ NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^j SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^k TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l Japan Osteoporosis Foundation   (Japan)

^m RESEARCH INSTITUTE AND PRACTICE FOR INVOLUTIONAL DISEASES   (Japan)

more..

Author keywords

25 hydroxyvitamin D; Bisphosphonate; Osteoporosis; Quality of life; Undercarboxylated osteocalcin

Indexed keywords

25 HYDROXYVITAMIN D; FARNOQUINONE; OSTEOCALCIN; RISEDRONIC ACID; WARFARIN; 25-HYDROXYVITAMIN D; BONE DENSITY CONSERVATION AGENT; ETIDRONIC ACID; VITAMIN D;

AGED; ARTICLE; BODY HEIGHT; BODY MASS; BONE DENSITY; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EQ 5D; FEMALE; FOLLOW UP; FRACTURE; GLOMERULUS FILTRATION RATE; HUMAN; JAPANESE (PEOPLE); JOQOL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK FACTOR; RISK REDUCTION; SAMPLE SIZE; SPINE FRACTURE; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG EFFECTS; METABOLISM; OSTEOPOROSIS; SPINAL FRACTURES;

AGED; BODY MASS INDEX; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; OSTEOCALCIN; OSTEOPOROSIS; PROSPECTIVE STUDIES; SPINAL FRACTURES; VITAMIN D; VITAMIN K 2;

EID: 84904664260     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-013-0491-4     Document Type: Article

References (41)

1. Orimo H (2007) The Japanese guidelines for the prevention and treatment of osteoporosis (2006 Edition). Osteoporos Jpn 15:351-355
2. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP binding proteins, including rats. J Bone Miner Res 13:581-589 (Pubitemid 28163009)
3. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker R, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB, For the Alendronate Phase III Osteoporosis Treatment Study Group (1995) Effects of oral alendronate on bone mineral density and the incidence of fracture in postmenopausal osteoporosis. New Engl J Med 333:1437-1443
4. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE, For the Fracture Intervention Trial Group (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fracture. Lancet 348:1535-1541 (Pubitemid 26411651)
5. Harris ST, Watts NB, Genant HK, McKeever EF, Hoseyni MS, Axelrod DW, Miller PD, Vertebral Efficacy with Risedronate Therapy (VERT) study group (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: randomized controlled trial. JAMA 282:1344-1352 (Pubitemid 29483192)
6. Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429-1437
7. Tsugawa N, Shiraki M, Suhara Y, Kamao M, Ozaki R, Tanaka K, Okano T (2008) Low plasma phylloquinone concentration is associated with high incidence of vertebral fracture in Japanese women. J Bone Miner Metab 26:79-85 (Pubitemid 350308003)
8. Kaneki M, Hodges SJ, Hosoi T, Fujiwara S, Lyons A, Crean SJ, Ishida N, Nakagawa M, Takeuchi M, Sano Y, Mizuno Y, Hoshino S, Miyao M, Inoue S, Horiki K, Shiraki M, Ouchi Y, Orimo H (2001) Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2: possible implications for hip fracture risk. Nutrition 17:315-321 (Pubitemid 32454984)
9. Cheung AM, Tile L, Lee Y, Tomlinson G, Hawker G, Scher J, Hu H, Vieth R, Thompson L, Jamal S, Josse R (2008) Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial. PLoS Med 14:e196
10. Iwamoto J, Takeda T, Ichimura S (2001) Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate. J Orthop Sci 6:487-492 (Pubitemid 34019555)
11. Shiraki M, Shiraki Y, Aoki C, Miura M (2000) Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 15:515-521 (Pubitemid 30134096)
12. Inoue T, Fujita T, Kishimoto H, Makino T, Nakamura T, Nakamura T, Sato T, Yamazaki K (2009) Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. J Bone Miner Metab 27:66-75
13. Ishida Y, Kawai S (2004) Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study. Am J Med 117:549-555 (Pubitemid 39304204)
14. Stevenson M, Lloyd-Jones M, Papaioannou D (2009) Vitamin K to prevent fractures in older women: systematic review and economic evaluation. Health Technol Assess 13:1-134
15. Fang Y, Hu C, Tao X, Wan Y, Tao F (2012) Effect of vitamin K on bone mineral density: a meta-analysis of randomized controlled trials. J Bone Miner Metab 30(1):60-68
16. Fukunaga M, Nakamura T, Shiraki M, Kuroda T, Ohta H, Hosoi T, Orimo H (2004) Absolute height reduction and percent height ratio of the vertebral body in incident fracture in Japanese women. J Bone Miner Metab 22:104-110 (Pubitemid 38405038)
17. Kumamoto K, Nakamura T, Suzuki T, Gorai I, Fujinawa O, Ohta H, Shiraki M, Yoh K, Fujiwara S, Endo N, Matsumoto T (2010) Validation of the Japanese osteoporosis quality of life questionnaire. J Bone Miner Metab 28:1-7
18. Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, de Groot LC, Hofman A, Witteman JC, van Leeuwen JP, Breteler MM, Lips P, Pols HA, Uitterlinden AG (2004) Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 350:2033-2041
19. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, Hannan MT, Cupples LA, Kiel DP (2004) Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 350:2042-2049 (Pubitemid 38596555)
20. Shiraki M, Kuroda T, Shiraki Y, Tanaka S, Higuchi T, Saito M (2011) Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment. J Bone Miner Metab 29:62-70
21. The Japanese version of National Cancer Institute-Common Toxicity Criteria version 2.0. Available at http://www.jcog.jp/doctor/tool/C-150-0011. pdf. Accessed 31 Jan 2012
22. Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T, Kaneda K, Morii H, Nawata H, Yamamoto K, Ohashi Y, Orimo H (2004) A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. J Bone Miner Metab 22:469-478 (Pubitemid 39248842)
23. Iwamoto J, Sato Y, Takeda T, Matsumoto H (2009) High-dose vitamin K supplementation reduces fracture incidence in post-menopausal women: a review of the literature. Nutr Res 29:221-228
24. Kushima Y, Ishii K, Shimizu K, Sasaki A, Yamamoto K, et al. (2007) Effect of combination therapy with risedronate and vitamin K2 for osteoporosis: Multicentre collaborative study. Preliminary report of a 1-year study. Osteoporos Jpn 15:234-237 (written in Japanese)
25. Dowd R, Recker RR, Heaney RP (2000) Study subjects and ordinary patients. Osteoporos Int 11:533-536
26. Okano T, Shimomura Y, Yamane M, Suhara Y, Kamao M, Sugiura M, Nakagawa K (2008) Conversion of phylloquinone (Vitamin K1) into menaquinone-4 (Vitamin K2) in mice: two possible routes for menaquinone-4 accumulation in cerebra of mice. J Biol Chem 283:11270-11279
27. Tabb MM, Sun A, Zhou C, Grün F, Errandi J, Romero K, Pham H, Inoue S, Mallick S, Lin M, Forman BM, Blumberg B (2003) Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem 278:43919-43927 (Pubitemid 37377131)
28. Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B, Inoue S (2006) Steroid and xenobiotic receptor SXR mediates vitamin K2-activated transcription of extracellular matrix-related genes and collagen accumulation in osteoblastic cells. J Biol Chem 281:16927-16934
29. Tsugawa N, Shiraki M, Suhara Y, Kamao M, Tanaka K, Okano T (2006) Vitamin K status of healthy Japanese women: age-related vitamin K requirement for gamma-carboxylation of osteocalcin. Am J Clin Nutr 83:380-386 (Pubitemid 44713201)
30. Shiraki M, Itabashi A (2009) Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study. J Bone Miner Metab 27:333-340
31. Szulc P, Chapuy MC, Meunier PJ, Delmas PD (1993) Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 91:1769-1774 (Pubitemid 23127383)
32. Seibel MJ, Robins SP, Bilezikian JP (1997) Serum undercarboxylated osteocalcin and the risk of hip fracture. J Clin Endocrinol Metab 82:717-718 (Pubitemid 27106575)
33. Vergnaud P, Garnero P, Meunier PJ, Bréart G, Kamihagi K, Delmas PD (1997) Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 82:719-724 (Pubitemid 27106576)
34. Luukinen H, Käkönen SM, Pettersson K, Koski K, Laippala P, Lövgren T, Kivelä SL, Väänänen HK (2000) Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res 15:2473-2478
35. Tanaka S, Narusawa K, Onishi H, Miura M, Hijioka A, Kanazawa Y, Nishida S, Ikeda S, Nakamura T (2011) Lower osteocalcin and osteopontin contents of the femoral head in hip fracture patients than osteoarthritis patients. Osteoporos Int 22:587-597
36. Shiraki M, Yamazaki Y, Shiraki Y, Hosoi T, Tsugawa N, Okano T (2010) High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment. J Bone Miner Metab 28:578-584
37. Matsumoto Y, Mikuni-Takagaki Y, Kozai Y, Miyagawa K, Naruse K, Wakao H, Kawamata R, Kashima I, Sakurai T (2009) Prior treatment with vitamin K(2) significantly improves the efficacy of risedronate. Osteoporos Int 20:1863-1872
38. Iwamoto J, Matsumoto H, Takeda T, Sato Y, Liu X, Yeh JK (2008) Effects of vitamin K(2) and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats. Calcif Tissue Int 83:121-128
39. Kuroda T, Shiraki M, Tanaka S, Ohta H (2009) Contributions of 25-hydroxyvitamin D, co-morbidities and bone mass to mortality in Japanese postmenopausal women. Bone 44:168-172
40. Nevitt MC, Thompson DE, Black DM, Rubin SR, Ensrud K, Yates AJ, Cummings SR (2000) Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med 160:77-85 (Pubitemid 30040976)
41. Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M, A-TOP (Adequate Treatment of Osteoporosis) research group (2011) Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT)-02. Curr Med Res Opin 27:1273-1284